Candeias
Member
- Joined
- Apr 29, 2018
- Messages
- 220
Cyproheptadine, a SET7/9 inhibitor, reduces hyperglycaemia-induced ER stress alleviating inflammation and fibrosis in renal tubular epithelial cells
"Results: SET7/9 and H3K4Me1 expression significantly increased with ER stress, inflammation, apoptosis, and fibrosis, in-vivo and in-vitro under hyperglycaemia. However, the cells treated with Cyproheptadine showed significant suppression of H3K4Me1 and reduction in ER stress, inflammation, apoptosis, and fibrosis.
Conclusion: Cyproheptadine prevented hyperglycaemia-induced renal fibrosis and inflammation by reducing H3K4Me1 expression and ER stress."
Chronic autologous immune complex glomerulopathy: effect of cyproheptadine
"(...)Immunized, untreated littermates served as controls (Groups IB and IIB). Proteinuria (> 10 mg. protein per day) began to appear among animals in the immunized untreated groups 4 to 5 weeks after immunization and affected 82 per cent of the rats in Control Group IB and 96 per cent of the rats in Control Group IIB 8 weeks after immunization. Proteinuria did not appear among the treated animals in Group IA until the sixth week after immunization and the prevalence of proteinuria in this group was lower than that of their controls (Group IB) at each weekly interval. In addition, the amount of protein excreted by the treated animals in Group IA that became proteinuric was significantly less than that of their controls in Group IB. Similarly, animals in Group IIA had a significantly lower prevalence of proteinuria compared to their controls (Group IIB) at each weekly interval. The quantity of proteinuria in the proteinuric animals of Group IIA was also lower than that of their controls, but the latter result was not statistically significant. Immunofluorescence microscopic examination of biopsies taken 6 weeks after immunization suggested that treated animals had a decreased deposition of immune complexes along the glomerular basement membrane compared to untreated controls. We conclude that the vasoactive amine antagonist, cyproheptadine, delays the onset of proteinuria and diminishes the degree of proteinuria in this experimental model of chronic immune-complex-mediated glomerular damage."
@looking2grow96
"Results: SET7/9 and H3K4Me1 expression significantly increased with ER stress, inflammation, apoptosis, and fibrosis, in-vivo and in-vitro under hyperglycaemia. However, the cells treated with Cyproheptadine showed significant suppression of H3K4Me1 and reduction in ER stress, inflammation, apoptosis, and fibrosis.
Conclusion: Cyproheptadine prevented hyperglycaemia-induced renal fibrosis and inflammation by reducing H3K4Me1 expression and ER stress."
Chronic autologous immune complex glomerulopathy: effect of cyproheptadine
"(...)Immunized, untreated littermates served as controls (Groups IB and IIB). Proteinuria (> 10 mg. protein per day) began to appear among animals in the immunized untreated groups 4 to 5 weeks after immunization and affected 82 per cent of the rats in Control Group IB and 96 per cent of the rats in Control Group IIB 8 weeks after immunization. Proteinuria did not appear among the treated animals in Group IA until the sixth week after immunization and the prevalence of proteinuria in this group was lower than that of their controls (Group IB) at each weekly interval. In addition, the amount of protein excreted by the treated animals in Group IA that became proteinuric was significantly less than that of their controls in Group IB. Similarly, animals in Group IIA had a significantly lower prevalence of proteinuria compared to their controls (Group IIB) at each weekly interval. The quantity of proteinuria in the proteinuric animals of Group IIA was also lower than that of their controls, but the latter result was not statistically significant. Immunofluorescence microscopic examination of biopsies taken 6 weeks after immunization suggested that treated animals had a decreased deposition of immune complexes along the glomerular basement membrane compared to untreated controls. We conclude that the vasoactive amine antagonist, cyproheptadine, delays the onset of proteinuria and diminishes the degree of proteinuria in this experimental model of chronic immune-complex-mediated glomerular damage."
@looking2grow96
Last edited:
